Last reviewed · How we verify
IPILIMUMAB
IPILIMUMAB is a CTLA-4-directed Blocking Antibody [EPC] drug. It is currently FDA-approved (first approved 2011) for Unresectable or Metastatic Melanoma, Adjuvant Treatment of Melanoma, Advanced Renal Cell Carcinoma.
Ipilimumab is a monoclonal antibody that targets cytotoxic T-lymphocyte protein 4, inhibiting its function. It is used to treat conditions such as malignant melanoma, metastatic melanoma, melanoma, small cell lung cancer, and lung cancer.
At a glance
| Generic name | IPILIMUMAB |
|---|---|
| Drug class | CTLA-4-directed Blocking Antibody [EPC] |
| Modality | Monoclonal antibody |
| Phase | FDA-approved |
| First approval | 2011 |
Approved indications
- Unresectable or Metastatic Melanoma
- Adjuvant Treatment of Melanoma
- Advanced Renal Cell Carcinoma
- Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer
- First-Line Unresectable or Metastatic Hepatocellular Carcinoma
- Previously Treated Unresectable or Metastatic Hepatocellular Carcinoma
- Metastatic Non-Small Cell Lung Cancer (PD-L1 ≥1%)
- Metastatic or Recurrent Non-Small Cell Lung Cancer
- Unresectable Malignant Pleural Mesothelioma
- Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Common side effects
- Fatigue
- Musculoskeletal pain
- Nausea
- Diarrhea
- Rash
- Decreased appetite
- Colitis
- Pruritus
- Pyrexia
- Vomiting
- Dyspnea
- Headache
Key clinical trials
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (PHASE1)
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (PHASE2)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (PHASE1, PHASE2)
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPILIMUMAB CI brief — competitive landscape report
- IPILIMUMAB updates RSS · CI watch RSS
Frequently asked questions about IPILIMUMAB
What is IPILIMUMAB?
What is IPILIMUMAB used for?
What drug class is IPILIMUMAB in?
When was IPILIMUMAB approved?
What development phase is IPILIMUMAB in?
What are the side effects of IPILIMUMAB?
Related
- Drug class: All CTLA-4-directed Blocking Antibody [EPC] drugs
- Indication: Drugs for Unresectable or Metastatic Melanoma
- Indication: Drugs for Adjuvant Treatment of Melanoma
- Indication: Drugs for Advanced Renal Cell Carcinoma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing